CREBH normalizes dyslipidemia and halts atherosclerosis in diabetes by decreasing circulating remnant lipoproteins.
Shimizu-Albergine M, Basu D, Kanter JE, Kramer F, Kothari V, Barnhart S, Thornock C, Mullick AE, Clouet-Foraison N, Vaisar T, Heinecke JW, Hegele RA, Goldberg IJ, Bornfeldt KE.
Shimizu-Albergine M, et al. Among authors: kothari v.
J Clin Invest. 2021 Nov 15;131(22):e153285. doi: 10.1172/JCI153285.
J Clin Invest. 2021.
PMID: 34491909
Free PMC article.